NORTHRIDGE, CA and CAMBRIDGE, UK--(Marketwired - Oct 9, 2013) - Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) today announced that it will be presenting at the upcoming 2013 Stem Cell Meeting on the Mesa. The event will take place on October 14-16, 2013 at the Estancia La Jolla Hotel in La Jolla, California. The Company will be presenting in Track 1 at 11:30 AM on Monday, October 14th as part of the conference's 3rd Annual Regen Med Partnering Forum.Presentation will be live-streamed on the day of the program. "We are pleased to be presenting at this leading regenerative medicine industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell SprayOn Skin is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among potential corporate partners and institutional investors as we approach FDA submission." This is a three-day conference organized annually by the Alliance for Regenerative Medicine, the California Institute for Regenerative Medicine and the Sanford Consortium for Regenerative Medicine with the intention of bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into … Continue reading →

Public release date: 9-Oct-2013 [ | E-mail | Share ] Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System ANN ARBOR, Mich. Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at the University of Michigan Health System the first two to receive the experimental injections in Michigan as part of a national clinical trial. Both research volunteers have returned home and will receive follow-up monitoring and testing to help U-M researchers assess the safety and any potential effect of the injections. Additional patients with the condition, also known as Lou Gehrig's disease, are being evaluated for possible participation in the trial at U-M and Emory University. The Phase II trial is approved by the U.S. Food and Drug Administration and funded by Neuralstem, Inc., the Maryland-based company whose stem-cell product the trial is testing. It seeks to study any effect that injected stem cells might have on motor neurons muscle-controlling nerve cells that die in ALS patients, eventually robbing them of the ability to walk, speak and breathe. Eva L. Feldman, M.D., Ph.D., the Russell N. DeJong professor of neurology at the U-M Medical School and director of the A. Alfred … Continue reading →

LOS ANGELES , Oct. 9, 2013 /CNW/ - Dr. Rongxiang Xu , the founder of "human body regenerative restoration science" and the patentee of damaged organ regeneration- a top priority claimed in President Obama's 2013 State of the Union, addresses the ongoing lawsuit against Nobel Committee and its continuous false advertisement of fake pluripotent stem cell during the past year since Dr. Xu initially filed his lawsuit against the Academy citing, among other claims, libel and unfair competition. Given the winners of 2013 Nobel Prize in Physiology or Medicine were disclosed this week and the Nobel Assembly has not yet made any clarification on its 2012 Prize in Medicine while continuing with its endorsement and false advertisement of fake pluripotent stem cells, Dr. Xu had to come out and tell the public why he sued the Nobel Assembly in 2012 and the progress of the lawsuit. On October 8, 2012 , The Nobel Assembly awarded the Nobel Prize in Physiology or Medicine to Shinya Yamanaka and another expert in nuclear transfer for artificially creating the pluripotency of human somatic cells. In the awarding press release and advertising documentary, the Nobel Assembly stated clearly that the prize winner successfully converted somatic … Continue reading →

Newswise ANN ARBOR, Mich. Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at the University of Michigan Health System the first two to receive the experimental injections in Michigan as part of a national clinical trial. Both research volunteers have returned home and will receive follow-up monitoring and testing to help U-M researchers assess the safety and any potential effect of the injections. Additional patients with the condition, also known as Lou Gehrigs disease, are being evaluated for possible participation in the trial at U-M and Emory University. The Phase II trial is approved by the U.S. Food and Drug Administration and funded by Neuralstem, Inc., the Maryland-based company whose stem-cell product the trial is testing. It seeks to study any effect that injected stem cells might have on motor neurons muscle-controlling nerve cells that die in ALS patients, eventually robbing them of the ability to walk, speak and breathe. Eva L. Feldman, M.D., Ph.D., the Russell N. DeJong professor of neurology at the U-M Medical School and director of the A. Alfred Taubman Medical Research Institute, is the principal investigator for the trial. Feldman serves as an unpaid consultant to the … Continue reading →

NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the Regen Med Partnering Forum during the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled to speak at 11:00 a.m. Pacific Time on Monday, October 14, at the Estancia La Jolla Hotel in La Jolla, Calif. A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine's (ARM) website shortly after the event. The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM), and ARM. The conference brings together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The first two days of the conference, October 14-15, features the Regen Med Partnering Forum, the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. … Continue reading →